Outcome Predictors for Patients Aged 55 Years and Older With Acute Lymphoblastic Leukemia: a Retrospective Study From the HARMONY Big Data Platform
Turki AT, Neuendorff NR, Taiji R, et al.
EHA 2024
- 欧洲血液年会 2024
| 肿瘤 | 白血病 | 血液肿瘤
An Indirect Comparison of Elranatamab’s Progression-Free Survival and Overall Survival From MangetisMM-3 vs Country-Specific Treatment Regimens From Real-World Data Sources
Costa LJ, Hebraud B, LeBlanc TW, et al.
EHA 2024
- 欧洲血液年会 2024
| 肿瘤 | 血液肿瘤 | 易瑞欧
Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Vs Teclistamab in Patients With Triple-Class Exposed/Refractory Multiple Myeloma
Mol I, Hu Y, LeBlanc TW, et al.
EHA 2024
- 欧洲血液年会 2024
| 肿瘤 | 血液肿瘤 | 易瑞欧
Multiple Myeloma Experiences and Preferences: a Qualitative Study of Patients and Care Partners
Flora DR, Byrd R, Platt D, et al.
EHA 2024
- 欧洲血液年会 2024
| 肿瘤 | 血液肿瘤
Patient-Reported Outcomes Among Patients With Triple-Class Refractory Multiple Myeloma Initiating a New Line of Therapy in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study
Charalampous C, Kumar SK, Parrondo R, et al.
EHA 2024
- 欧洲血液年会 2024
| 肿瘤 | 血液肿瘤
Characteristics and Clinical Outcomes of Patients With Triple-Class Exposed Multiple Myeloma Across Europe: Results From the HARMONY Alliance Big Data Platform
López C, Mas A, de la Rubia J, el al.
EHA 2024
- 欧洲血液年会 2024
| 肿瘤 | 血液肿瘤
Assessing the Role of Practice Setting on Disparities in Clinical and Treatment Outcomes Among Patients With Newly Diagnosed Multiple Myeloma
Meche A, Faucher A, Kyle RP, et al.
EHA 2024
- 欧洲血液年会 2024
| 肿瘤 | 血液肿瘤
Characterization of the BCMA Epitope Bound by BCMA-CD3 T Cell Engager Elranatamab
Josic M, Schweibold R, Mosyak L, et al.
EHA 2024
- 欧洲血液年会 2024
| 肿瘤 | 血液肿瘤 | 易瑞欧
Real-World Treatment Trends and Triple Class Exposed Status in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Retrospective Claims Database Study
Xu L, Moribe T, Take K, et al.
EHA 2024
- 欧洲血液年会 2024
| 肿瘤 | 血液肿瘤 | 易瑞欧
